Stem Cell Clinic

Global Stem Cell Therapy Market – Analysis, Technologies and Forecasts to 2021 – Increasing Demand to Develop … – Yahoo Finance

By adminApril 24, 2017Uncategorized

DUBLIN, April 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Stem Cell Therapy Market 2017-2021" report to their offering.

Research and Markets Logo

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 Car T Cell Based Therapies in Clinical Pipeline … – Yahoo Finance

By adminApril 24, 2017Uncategorized

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering.

The report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

Companies Mentioned

Key Topics Covered:

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

3. Principle of Chimeric Antigen Receptor Design

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase

8. Global Market Scenario of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

10. Global CAR T Cell Therapy Market Dynamics

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscap

For more information about this report visit http://www.researchandmarkets.com/research/3h29l7/global_car_t_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424006562/en/

See the article here:
Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 Car T Cell Based Therapies in Clinical Pipeline ... - Yahoo Finance

HemaCare Will Attend International Society of Cell Therapy in London – Yahoo Finance

By adminApril 24, 2017Uncategorized

LOS ANGELES--(BUSINESS WIRE)--

HemaCare Corporation (HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Cell Therapy (ISCT) in London, UK, May 3-6, 2017. This year marks the 25th anniversary of the ISCT, a global society that unites clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into clinical practice. HemaCare will meet with its customers and European distributors at the conference and showcase its growing portfolio for cell therapy developers around the world.

Attending this meeting enables us to capture the latest developments in cell therapy and better serve our customer needs, said Pete van der Wal, Chief Executive Officer for HemaCare.The field of cell therapy is rapidly evolving. Our products and services are embedded in some of the most critical phases of translational research, enabling scientists to work with high quality human cells from our well-characterized donor pool.

The conference is being held at ExCel London Conference Center. Look for us there, or view our products and services at http://www.hemacare.com.

About HemaCare

HemaCare specializes in the customization of human-derived biological products and services for customers research and cell therapy protocols. HemaCares network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCares isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare's extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.

For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit http://www.hemacare.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005274/en/

Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage – BU News Service

By adminApril 24, 2017Stem Cell Treatment

Skiing in Aspen, Sean Fair mistimed a landing and felt a shooting pain in his right knee as he crumpled into the snow. He had to slide down the steep slope on his left ski. The doctor revealed that Fairs agony originated from a quarter-sized hole in the cartilage of his knee.

For an active person like Fair, traditional surgery options, like a total knee replacement, restrict motion and are less than ideal. Advances in experimental cartilage repair stem cell treatments, however, now offer new opportunities for young patients to preserve mobility, that defining value of youth.

Fair played football, among other sports, in high school. He played tennis in college and continued to play until he had his ski incident at the age of 31.

All of a sudden, not being able to do anything, I felt 80, he said. All my friends would play tennis together but I would have to sit back and watch.

Sean Fair was diagnosed with OCD, or osteochondritis dissecans. This condition typically develops in teenagers but doesnt usually present symptoms until adulthood when the joint experiences some form of trauma. OCD lesions involve holes, cracks, or loose articular cartilage in a joint.

Fair met with Dr. Andreas Gomoll, an orthopedic surgeon at the Brigham and Womens Hospital in Boston. They discussed knee replacement surgery, microfracture surgery and the possibility of using healthy cartilage from a cadaver donor.

Knee replacement surgery for patients as young as Fair often results with low satisfaction. People who receive the standard metal and plastic knee replacement are functionally limited and face unexpected physical challenges when it comes to activities more intense than a walk. Microfracture surgery would be better, but Fairs injury was too large for that to be practical. Fair and Gomoll decided to wait for a cadaver donor. While waiting, however, Fair joined a clinical trial to test a new approach that would fill the gap in his cartilage with stem cells.

Stem cells can be thought of as undecided cells. Theyre mostly present in embryos and neonates, but they are also found in adults as well. Given the correct environment, and depending on the type of stem cell, they can become more specific cells, like muscle cells or cartilage-forming cells. In Fairs case, Gomoll used donated umbilical cord stem cells from healthy babies delivered in the US. Umbilical cord stem cells are useful because they are able to morph into cartilage-forming cells, they dont require the destruction of an embryo and they have immunosuppressive properties that wouldnt cause Fairs body to reject them.

Anatomical representation of the human knee.

The procedure looked simple. Gomoll made a vertical incision in Fairs kneecap, cutting through the skin and the yellow fat to expose the white cartilage. Gomoll used stainless steel tools to clamp open the incision, while he used a metal ring spanner to scrape the edges of the cartilage pothole. (Picture using a spoon to carve a hole in a large eraser.) Next, the surgeon drilled seven coffee stirrer-sized holes into the bone at the bottom of the quarter-sized pothole. He injected the clear stem cell gel into each coffee stirrer-sized hole and then filled the quarter-sized hole up to its edges with the rest of the stem cell gel. Gomoll smoothed down the stem cell gel like icing on a cake. Then he sutured the wound closed.

Fair wasnt quick to start walking right after the procedure. His knee needed to heal and then he would have to follow a strict rehabilitation process of weekly physical therapy sessions.

Months after his surgery, the stem cells in Fairs knee developed into chondrocytes, cells that secrete a matrix of cartilage, and sealed the pothole in Fairs knee. As of now, Fair is thankful for his treatment. His right knee has healed, but hes still not at 100 percent.

My other knee unfortunately, because of all the issues the [right knee] had, also needs reconstruction, Fair said. Ive got to be careful when I carry my two-and-half-yearold down the steps. Functionally I can walk. I can chase him. I can outrun him, still. Other than that, its not a lot of peripheral movement I can do yet.

According to Gomoll, about 15 other Americans have received the same experimental treatment as Fair. Before this therapy can be offered at any hospital in the US, the clinical trial must obtain FDA approval after proving its efficacy with a larger, more randomized sample of patients. But Gomoll doesnt seem too worried. He says hundreds of patients in South Korea have already undergone the same procedure. Getting there will take some time and money; running comprehensive trials is expensive. Once the procedure is approved, Gomoll imagines thousands of cartilage damaged patients like Fair would potentially be treated with stem cells in the United States.

The rest is here:
Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage - BU News Service

Stem cells help researchers identify neuronal defects causing Angelman syndrome – Science Daily

By adminApril 24, 2017Stell Cell Research

Stem cells help researchers identify neuronal defects causing Angelman syndrome
Science Daily
Angelman patients are very active in the ongoing research into the disorder. The induced pluripotent stem cells used in Levine's research were derived from skin and blood cells donated by people with Angelman. Those cells were then reprogrammed into ...

and more »

View original post here:
Stem cells help researchers identify neuronal defects causing Angelman syndrome - Science Daily

Chinese space scientists study human organs in space – Space Daily

By adminApril 23, 2017Embryonic Stem Cells

Scientists around the world are looking for the "keys" to enable humans to regrow tissues or organs lost due to illness or injury, just like gecko can regrow a tail. Their quest now extends into space. Stem cell research on Tianzhou-1, China's first cargo spacecraft, is far from realizing this dream, but it's the first step to explore the possibility.

Scientists from the Institute of Zoology of the Chinese Academy of Sciences (CAS) are conducting experiments on Tianzhou-1, which launched Thursday, to study the effects of micro-gravity on embryonic stem cell proliferation and differentiation.

The spacecraft is carrying embryonic stem cells and embryoid bodies of mice. Scientists will observe the process of their proliferation and differentiation in space through telescope images. Parallel experiments will be conducted on the ground to compare the results, says lead researcher Duan Enkui.

"We hope to get an initial understanding about the space micro-gravity effects on stem cell proliferation and differentiation," said Duan.

The basis of tissue engineering and regenerative medicine research, stem cell biology is regarded as one of the most important research fields of the 21st Century.

Embryonic stem cells are pluripotent cells that have the potential to become any type of cell in the body. One of the main characteristics of stem cells is their ability to self-renew or multiply while maintaining the potential to develop into other types of cells. Stem cells can become cells of the blood, heart, bones, skin, muscles, brain or other body parts. They are valuable as research tools and might, in future, be used to treat a wide range of ailments.

The study of micro-gravity's effects on the proliferation and differentiation of stem cells is a hot topic in the field of space life science.

"In ground experiments simulating micro-gravity conditions, we found the differentiation ability of mouse embryonic stem cells is enhanced. We also discovered the key gene responsible for this change and the molecular signaling pathway," says Lei Xiaohua, a member of the research team.P "Can we use micro-gravity conditions to realize large-scale proliferation of stem cells and tissue engineering construction? That's what we want to find out," says Lei.

"As the ground experiments are conducted in simulated micro-gravity, we must move the study to a real micro-gravity environment in space to understand how it will affect the proliferation and differentiation of embryonic stem cells."

The experiment might provide a new method to better realize in-vitro expansion of embryonic stem cells, and might explore a new way to apply multi-potent stem cells in tissue engineering and regenerative medicine, Lei says.

"Maybe scientists will be able to induce stem cells to grow into certain tissues or organs in space in the future to serve people on earth. In another scenario, if a human is injured and loses organs in future space migration, the lost organs might be regenerated," says Lei.

Previously, the research team conducted a series of space life science experiments on China's recoverable satellites Sj-8 and Sj-10.

"We expect to continue our research into embryonic stem cells on China's future space station. We aim to try to culture functional tissues, such as heart, kidney, liver and spleen tissues," Lei says.

The current life science experiments on Tianzhou-1 are remotely controlled, which is very difficult, he adds. Scientists hope to enter China's space station in future to personally conduct the experiments.

Source: Xinhua News Agency

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

Originally posted here:
Chinese space scientists study human organs in space - Space Daily

Are human space babies conceivable? – Space Daily

By adminApril 23, 2017Embryonic Stem Cells

As astronauts continue to break records for time spent in space and manned Mars exploration is under discussion, scientists in China have begun a groundbreaking study to determine if humans can reproduce in space.

Scientists will for the first time conduct an experiment to induce the differentiation of human embryonic stem cells into germ cells on China's first cargo spacecraft, Tianzhou-1.

The experiment aims to study the effects of the space environment on human reproduction, beginning with the study of microgravity on human stem cells and germ cells, says Kehkooi Kee, lead researcher on the project.

Kee, a Malaysia Chinese professor at China's prestigious Tsinghua University, says the unprecedented experiment will study the basic development and maturation of germ cells in the micro-gravity environment, and the developmental potential of human embryonic stem cells.

The research is expected to provide a theoretical basis and technical support to solve the possible problems of human reproduction caused by the space environment, Kee said.

"It's an important experiment because it is the first step towards directly understanding human reproduction during space exploration," he says.

What kind of difficulties could people face by having children in space?

Experts say that in the known space environment, micro-gravity, radiation and magnetic fields could have a great impact on human reproduction. Among these factors, micro-gravity could be the largest challenge.

At the cellular level, micro-gravity might affect cell division or polarity. The cells of living organisms contain many organic molecules. These molecules and cells are evolved to function under the earth gravitational force. But scientists are still not clear how micro-gravity could affect the physical force governing the molecular interactions and developments of the cells, says Kee.

The United States, Russia and Europe have conducted many space experiments to examine if micro-gravity is harmful to astronauts, especially the effects on the muscle and bones. However, microgravity effect on human reproductive capacity has been rarely studied.

Previous research in this area mainly focused on monitoring the reproductive hormone levels of astronauts. Due to the ethical and physical constraints, it has been very difficult to directly obtain and study their germ cells.

"If we aim to directly study human reproductive biology in space, we need to build an in-vitro platform to study the germ cells. So we chose to use human embryonic stem cells to differentiate into germ cells," says Kee.

In 2009, he and his colleagues used human embryonic stem cells to create human primordial germ cells and sperm-like cells for the first time. They published their research in the academic journal Nature.

Currently, the team has successfully obtained egg-like cells from human embryonic stem cells and will be publishing this novel finding soon.

Human embryonic stem cells can be induced into primordial germ cells and further differentiate into sperm-like or egg-like cells. But differentiating embryonic stem cells into sperm-like or egg-like cells is very difficult because they require more developmental steps and more cellular factors, says Kee.

Although other scientists have conducted similar experiments, none has made human germ cells differentiate into such a mature state as Kee's team has.

"We have compared the in-vitro cultured cells with in-vivo cells, and found they have many similar characteristics. But we can only call the in-vitro ones sperm-like cells or egg-like cells, because we still can't prove they are exactly the same until we conduct functional experiments," Kee says.

So far, all such experiments have been conducted on the ground, so scientists do not know whether micro-gravity will affect the differentiation of human embryonic stem cells and the formation of germ cells.

"In the experiments on the ground, it usually takes six days to culture and obtain primordial germ cells, and about two weeks to form sperm-like or egg-like cells," says Kee.

"The experiment on Tianzhou-1 will last 30 days. To what extent the human embryonic stem cell can differentiate in space is still unknown. Will the process be delayed? If so, by how much?" asks Kee, adding they expect to see at least the first stage of the primordial germ cells appear.

Scientists on the ground will remotely control the research equipment to change the cell-culture medium to induce the human embryonic stem cells to differentiate into germ cells. Images of the cells under the microscope will be transmitted to earth.

Source: Xinhua News Agency

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

View post:
Are human space babies conceivable? - Space Daily

Stem cell-based treatment prevents transplant rejection, in animal study – The San Diego Union-Tribune

By adminApril 23, 2017Stem Cell Treatment

Organ transplant rejection might eventually be preventable by giving recipients an immune-suppressing vaccine derived from induced pluripotent stem cells, according to a study led by Japanese researchers.

In mice, the treatment allowed permanent acceptance of heart grafts by selectively inhibiting the immune response to the donor graft, said the study, published April 20 in Stem Cell Reports. The work might also be applicable to autoimmune diseases, the study said.

The study can be found at j.mp/ipscden. The co-first authors were Songjie Cai, Jiangang Hou, and Masayuki Fujino. The senior author was Xiao-Kang Li. All are of the National Research Institute for Child Health and Development in Tokyo.

The IPS cells were matured into donor-type regulatory dendritic cells (DCregs) which in turn caused production of tolerance-inducing regulatory T cells, or Tregs, that allow the graft to be treated as self.

While the technology looks good, a UC San Diego stem cell researcher said it faces a number of hurdles that make practical use of it difficult, especially the difficulty in producing the donor-derived regulatory cells in time to be of use in a transplant.

Use of these Tregs and immature DCregs for transplant has been investigated for several years now. In theory, they would provide a better method of preventing rejection than immunosuppressive drugs that knock down immune functioning across the board.

However, activating Tregs must be done precisely, or other T cell types will be activated, increasing the risk of rejection.

The study found that donor-type dendritic cells reliably activated Tregs and not the other types. Peptide antigens from the graft directed naive CD4+ T cells to mature into donor-specific Tregs, providing a selective immune signal to tolerate the graft.

Use of IPS cells for producing these immune regulatory cells is quite novel, said Dan Kaufman, director of cell therapy at UC San Diego, and affiliated with the universitys Sanford Stem Cell Clinical Center.

Obviously, it fits my interest in making immune cells from ES and IPS cells, Kaufman said. The ability to use these cells to suppress transplant rejection seems quite strong. I think the data is all good.

That said, the findings could be strengthened by extending the work from animals to human xenografts, he said. That would demonstrate that human IPS cells can similarly function, although it would be challenging.

Another limitation is the need to use donor-derived cells to induce immune tolerance.

How you would translate that would be unclear to me, Kaufman said.

Are you going to get a heart and then make IPS cells from that donor, which obviously you couldnt do in a reasonable time frame? Could you create a bank of these types of cells that might be suitable for certain patient populations with certain HLA types? Im not sure. I think that gets a little more speculative.

Another speculative possibility is to make the donor-derived IPS cells grow into an organ, and then also create the immune-regulating cells from these IPS cells to selectively induce tolerance.

But were still, I think, a long ways off from having IPS-derived organs, he said.

Autoimmune disease treatment with this technology is worth exploring, Kaufman said. In that case, the IPSCs would be made from the patients themselves.

More than 118,000 Americans are on the waiting list for an organ transplant, according to the Organ Procurement and Transplantation Network.

bradley.fikes@sduniontribune.com

(619) 293-1020

View post:
Stem cell-based treatment prevents transplant rejection, in animal study - The San Diego Union-Tribune

Sanford Medical Center has breakthrough in curing Rotator Cuff … – INFORUM

By adminApril 22, 2017Stem Cell Medical Center

A team from Sanford Medical Center in Fargoand Sioux Falls, S.D., could hold the key to repairing this shoulder injury by using our own bodies.

It's the first Food and Drug Administration-approved clinical trial of its kind in the country.

Gary Johnson, 64, hopes to be a candidate and he, like many of us, has nagging rotator cuff pain.

"That one repetitive motion has worn this one point out in the front." Johnson says.

He hopes to meet the criteria and be enrolled in this groundbreaking research at Sanford.

"I was asked if I had a vision for the future where did I think it would be, not unique to me, but the future is in biologics." says Dr. Mark Lundeen, a doctor at Sanford.

They will use a person's fat-derived stem cells to treat rotator cuff injury.

"If we can prove the stem cells induce a healing response and prevent progression, that changes everything for a large number of people." Lundeen says.

Eighteen patients will be in the study.

Some will receive the stem cells; others will not.

The FDA will then look at the data, and using stringent scientific rigor, decide if the United States will welcome this treatment.

With FDA approval, the stem cell treatment could be available in the U.S. within two years.

The rest is here:
Sanford Medical Center has breakthrough in curing Rotator Cuff ... - INFORUM

Elder grad, Wright State athlete considered for stem cell study – Cincinnati.com

By adminApril 22, 2017Stem Cell Medical Center

George and Kim Custer, parents of Ryan Custer, provide an update on their son's condition.(Photo: The Enquirer/Sheila Vilvens)Buy Photo

Reading from a prepared statement, pausing to choke back emotions a few times, the father of the recently injured Wright State University basketball player and Elder High School graduate, Ryan Custer, offered an update on his sons condition.

Hes shown some improvement in the past few days, George Custer said during a news conference at University of Cincinnati Medical Center. He has some feeling in his fingers and some slight movement, he said. Hes also felt the tops of his feet being rubbed and said theres some tingling in his thighs and feet.

Ryan Custer suffered a spinal injury April 8 after he reportedly attempted to dive into a make-shift pool while at a party near Miami University. He was flown to UC Medical Center where he underwent surgery and has remained since the accident.

Right now Ryan is being considered for a stem cell study at Rush University in Chicago, George Custer said.

He leaves Friday morning but there are no guarantees he will be accepted into the study. He will be evaluated for five days.

Hopefully hell pass the test theyre going to give him and hell receive an injection and hell be there for seven to nine days afterward for further evaluation, Custer said. In-house rehabilitation will follow at a yet-to-be-determined location.

Custer, with his wife, Kim, by his side, expressed gratitude for the prayers, supportand kindness shown to his family and Ryan over the past week and for the generous donations to the GoFundMe page set up for Ryan.

The Ryan Custer 33 Recovery Fund has raised more than $81,000 towards its $100,000 goal.

Those donations will be extremely helpful in ensuring Ryan receives the best care that he can get so we can get him back to the way he was, Custer said.

He asked for continued prayers as well.

The more prayers we have, maybe God will answer our prayers and give him the healing that he needs, he said.

For those wanting to follow his progress, updates will continue to be provided on Ryan Custers Recovery Care Page on Facebook.

Read or Share this story: http://cin.ci/2pz0wHn

Here is the original post:
Elder grad, Wright State athlete considered for stem cell study - Cincinnati.com